---
title: "NHS Framework for the Midlands and East, Branded Medicines - Tranche B plus Cytokine Modulators and other Monoclonal Antibodies."
ocid: "ocds-h6vhtk-029565"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-029565"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-029565.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-029565.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)"
published: "2021-02-23"
---

# NHS Framework for the Midlands and East, Branded Medicines - Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)  
Current stage: Award  
OCID: ocds-h6vhtk-029565

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-029565)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-029565.json)

## Summary

The NHS Commissioning Board, operating as NHS England, is conducting a tender for the "NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies." This procurement process falls under the goods category, specifically targeting pharmaceutical products. The framework period spans from 1 March 2021 to 28 February 2023, with potential extensions. Notably, bids were submitted for various lots within the framework, showcasing an active competitive environment as of 23 February 2021.

This tender provides significant opportunities for businesses in the pharmaceutical sector, particularly those specialising in branded medicines, cytokine modulators, and monoclonal antibodies. Companies with expertise in producing these products, especially large or SME pharmaceutical firms, would be well-suited to compete, leveraging their capabilities to meet the NHS's evolving healthcare needs. Participants can also establish long-term relationships with NHS England, enhancing their market presence in the UK healthcare system.

## Notice

CM/PHR/20/5591/01 - Midlands and East, Branded Medicines - Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5591/02 - Midlands and East Branded Medicines - Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 monthsCM/PHR/20/5591/03 - Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021CM/PHR/20/5591/04 - Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021

### Lot Information

Lot 1: Midlands and East (MAE) Tranche B

CM/PHR/20/5591/01 - NHS Framework for the Midlands and East, Branded Medicines - Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Lot 2: Midlands and East Cytokine Modulators and other monoclonal antibodies

CM/PHR/20/5591/02 - NHS Framework for the Midlands and East Branded Medicines - Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Lot 3: (LNW) - Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma

CM/PHR/20/5591/03 - NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Lot 4: (SOFE) - Interleukin Inhibitors, JAK Inhibitors, Migraine & Asthma

CM/PHR/20/5591/04 - NHS Framework agreement for the supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/003581-2021 |
| Notice type | Award Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 23 Feb 2021 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 25 Jan 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 37 |
| Supplier names | ACCORD-UK; AMGEN; ASTRAZENECA; AVENTIS PHARMA LTD T/A SANOFI; BAYER; BIOGEN; BRISTOL MYERS SQUIBB; CELLTRION HEALTHCARE UNITED KINGDOM; CST PHARMA; DAIICHI SANKYO; DAY LEWIS MEDICAL; DR.REDDY'S LABORATORIES (UK; ELI LILLY; FERRING PHARMACEUTICALS; GEDEON RICHTER; GILEAD SCIENCES; IPSEN; JANSSEN-CILAG; LEO PHARMA; MERCK SERONO; MERCK SHARP AND DOHME (MSD; MERCK SHARPE AND DOHME (UK; MYLAN; NAPP PHARMACEUTICALS; NOVARTIS PHARMACEUTICALS; NOVO NORDISK; PFIZER; ROCHE PRODUCTS; ROVI BIOTECH; SANDOZ; SOBI (SWEDISH ORPHAN BIOVITRUM; TAKEDA; TECHDOW PHARMA ENGLAND; TEVA; THORNTON AND ROSS; UCB PHARMA; UL GLOBAL PHARMA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 23 Feb 2021 at 13:53 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/003581-2021

## Notice URLs

- http://napp.co.uk/
- http://www.amgen.com
- http://www.astrazeneca.com
- http://www.bayer.co.uk
- http://www.biogen.uk.com
- http://www.celltrionhealthcare.com
- http://www.daiichi-sankyo.co.uk
- http://www.daylewis.co.uk
- http://www.drreddys.com
- http://www.ferring.co.uk
- http://www.gedeonrichter.co.uk
- http://www.janssen.co.uk
- http://www.leo-pharma.com
- http://www.lilly.com
- http://www.msd-uk.com
- http://www.mylan.co.uk
- http://www.pfizer.co.uk
- http://www.rovi.es/uk
- http://www.sandoz.com
- http://www.sobi-uk.co.uk
- http://www.techdow-pharma.co.uk/
- http://www.tevauk.com
- http://www.ul-globalpharma.com
- https://ted.europa.eu/udl?uri=TED:NOTICE:470495-2020:TEXT:EN:HTML
- https://www.england.nhs.uk/
- https://www.gilead.com/
- https://www.gov.uk/courts-tribunals
- https://www.ipsen.com/uk/
- https://www.merckgroup.com/uk-en
- https://www.novartis.co.uk/
- https://www.novonordisk.co.uk/
- https://www.roche.co.uk/
- https://www.sanofi.co.uk/
- https://www.takeda.com/en-gb/
- https://www.thorntonross.com/
- https://www.ucbpharma.co.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-029565. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-029565.json.